ライフサイエンスコーパス: thrombolytics

1 sure of thrombus to endogenous and exogenous thrombolytics.

2 use of the limited effectiveness of existing thrombolytics.

3 ing vessel recanalization with intraarterial thrombolytics.

4 file of abciximab was observed between the 2 thrombolytics.

5 response venous thrombi to catheter-directed thrombolytics.

6 tment algorithm, especially for early window thrombolytics.

7 tracerebral haemorrhage after treatment with thrombolytics (2 [7%] telemedicine vs 2 [8%] telephone,

8 from baseline to the fifth year: intravenous thrombolytics (42.09% versus 72.84%), early antithrombot

9 tion, and the concomitant use of intravenous thrombolytics, among others.

10 wo hundred fifty-eight AMI patients from the Thrombolytics and Myocardia Infarction phase 7 and Globa

11 ion, (2) receipt of acute stroke treatments (thrombolytics and thrombectomy), and (3) health outcomes

12 sing stent retrievers, aspiration catheters, thrombolytics, and (in selected patients) carotid stenti

13 ed that ex vivo attachment of bioscavengers, thrombolytics, and nanoparticles (NPs) to glycophorin A

14 ilities, patients who received intracoronary thrombolytics, and those who received no medications wit

15 ral arterial access site, >6-Fr sheath size, thrombolytics, arterial dissection, fluoroscopy time >30

16 lready arrested, the difficulty of obtaining thrombolytics at the bedside rapidly enough to administe

17 We reported odds ratios (ORs) for use of thrombolytics, beta-blockers, ACE inhibitors, or aspirin

18 t indications for treatment with intravenous thrombolytics but were not eligible for treatment with e

19 elevation myocardial infarction who receive thrombolytics, clopidogrel therapy confers broad benefit

20 bition in myocardial infarction treated with thromboLYtics (COMPLY) and COMplement inhibition in Myoc

21 ion to a certified stroke center, receipt of thrombolytics (delivered using drip-and-ship and drip-an

22 d diagnosis of pulmonary embolism and use of thrombolytics during cardiopulmonary resuscitation may n

23 the lack of good data supporting the use of thrombolytics during resuscitation, the belief that thro

24 atments: coronary-artery reperfusion before, thrombolytics during, and beta-blockers, antiplatelet dr

25 Thrombolytics (eg, tissue-type plasminogen activator [tP

26 nother acute care hospital for evaluation of thrombolytics, endovascular therapy, or postthrombolytic

27 To increase the effective use of thrombolytics for acute stroke, the expertise of vascula

28 Rapid clearance of thrombolytics from blood following intravenous injection

29 iximab in combination with administration of thrombolytics has been shown to improve epicardial and m

30 ng stroke recovery long after the window for thrombolytics has passed.

31 Clinically approved thrombolytics have significant drawbacks, including blee

32 rdiopulmonary arrest and discuss the role of thrombolytics in cardiopulmonary resuscitation.

33 ted heparin was administered in 33 (87%) and thrombolytics in four (11%).

34 The use of thrombolytics in the treatment of vertebrobasilar occlus

35 .74-40.21 percentage points), and receipt of thrombolytics increased by 0.48 percentage points (95% C

36 Catheter-directed thrombolytics is the primary treatment used to relieve c

37 ysis (USAT), and administering lower dose of thrombolytics (LDT) is unclear.

38 l patient population, those not treated with thrombolytics (n = 228,512) and those given thrombolytic

39 assess their suitability for treatment with thrombolytics, on the basis of standard criteria.

40 associated with increased rates of receiving thrombolytics only for White patients.

41 enzyme elevation, some argue for the use of thrombolytics or catheter thrombectomy even for hemodyna

42 No patient received thrombolytics or surgical evacuation of clot.

43 By multivariable analysis, thrombolytics, prior myocardial infarction, advancing ag

44 coronary syndromes who are not eligible for thrombolytics reduced the composite of recurrent ischemi

45 le patients, ultraslow, low-dose infusion of thrombolytics seems effective and safe and may be prefer

46 gment elevation AMI and contraindications to thrombolytics should be strongly considered.

47 , occlusion location, and use of intravenous thrombolytics, to receive either normobaric hyperoxia co

48 Use of thrombolytics was associated with lower all-cause mortal

49 Intracatheter instillation of thrombolytics was more frequent in patients who received

50 thrombolytics (n = 228,512) and those given thrombolytics were 10.4%, 12.9% and 5.9%, respectively (

51 Intravenous thrombolytics were used at an overall rate of 25% (31 [2

52 Thrombolytics were used at presentation in 19 (35%) pati

53 imaging and new clinical trials that combine thrombolytics with other pharmacological and interventio